Fig. 1From: Characteristics of new users of recent antidiabetic drugs in Canada and the United KingdomPrevalence of comorbidities at baseline in the Canadian sites. Abbreviations: DPP-4i: dipeptidyl peptidase-4 inhibitors; SGLT-2i: sodium-glucose co-transporter-2 inhibitors; GLP-1 RA: glucagon-like peptide-1 receptor agonists. * Assessed in the 3 years prior to cohort entryBack to article page